MedTrace Logo

An Open-Label, Dose-Escalation Study of AZD2461

NCT01247168 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2012-06-06

No results posted yet for this study

Summary

This study is being conducted to test study drug AZD2461 to see how it may work to treat solid tumors. The main purpose of this study is to determine the safety and tolerability of AZD2461. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.

Conditions

  • Refractory Solid Tumors
  • Cancer Tumor

Interventions

DRUG

AZD2461

oral capsules, continuous dosing and intermittent dosing

Sponsors & Collaborators

Principal Investigators

  • Andrew Hughes, MA, MB, ChB, PhD, P · AstraZeneca

  • Dr. Jeffrey Infante, MD · Sarah Cannon Research Institute (SCRI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01247168 on ClinicalTrials.gov